Answers are grounded in this paper and cite their sources.
Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDITION3 ClinicalTrials.gov number, NCT01900665 .).
No takes yet. Share an insight, caveat, or question.
Honig et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: